# PREP-MEDS — 12-hour ingredient/formulation validation sprint

Start: 2026-11-06. Target: four 3-hour work blocks, not a guarantee of clinical approval.
Scope: active ingredient × clinically distinct formulation. Brands/aliases inherit validated group guidance; every canonical medication ID must be mapped and tested.

## Block 1 — inventory and safety triage (start now)
- [x] Enumerate `terminologyDataset.medications` into deterministic machine-readable manifest builder (`apps/web/lib/medication-validation-manifest.ts`); static artifact export and clinical metadata enrichment still pending.
- [ ] Deduplicate into ingredient/formulation review groups, preserve combinations and meaningful route/release differences.
- [x] Record exact provisional totals from CI run 42332062649: 436 canonical medications, 233 unique ingredient sets, 48 combination entries; all ingredient references resolved by passing inventory integrity test. Formulation adjudication and complete source manifest still pending.
- [x] Check PR #37 CI and repair regressions. Latest verified passing run: 42332062649 at commit 672d343f93d058648d18a3406c50ae90fb0c7dd2.\n- [x] Add initial medication inventory integrity tests (duplicate IDs, ingredient references, combinations, provisional grouping), commit 672d343.\n- [x] Capture exact inventory denominators from CI output (run 42332062649, job 128280587303).\n- [x] Commit machine-readable manifest builder and mapping tests (5f3d9ec, dc9b98f); fix TypeScript CI regression (0ed104b).\n- [ ] Adjudicate clinically distinct formulations and verify CI after fix.
Acceptance: committed manifest, exact denominators, zero silent unmapped IDs, CI status documented.

## Block 2 — antithrombotics (at +3 hours)
- [ ] FIRST verify Block 1 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Reconcile ASGE 2016 vs ACG/CAG 2022, BSG/ESGE 2021 and relevant current guidance per distinct antithrombotic group.
- [ ] Cover procedural bleeding risk, renal function, indication/thrombotic risk, interruption, bridging, restart, DAPT and aspirin.
- [ ] Add positive, negative, edge-case tests and source-linked conflict notes.
Acceptance: antithrombotic group-level review ledger and passing tests, or explicitly listed blockers.

## Block 3 — diabetes and other high-risk drugs (at +6 hours)
- [ ] FIRST verify Block 2 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Review insulin by basal/prandial/pump and clinically distinct formulation, GLP-1 agents, SGLT2 inhibitors, combinations and other high-risk periendoscopic drugs.
- [ ] Cross-check diet/prep/NPO timing and individualized prescriber approval; test type 1 basal and hypoglycemia safeguards.
- [ ] Map every brand/alias to the correct group; test no missing ingredients in combinations.
Acceptance: documented evidence, scenarios, tests, and unresolved cases.

## Block 4 — remainder, integration and final report (at +9 hours)
- [ ] FIRST verify Block 3 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Complete remaining group-level guideline reviews, mapping and regression coverage, prioritizing clinical risk.
- [ ] Run complete CI and build, check preview, reconcile audit ledger and count coverage.
- [ ] Report exact reviewed/total groups, mapped/total IDs, tests, unresolved discrepancies, clinical sign-off status.
- [ ] Merge only if CI passes AND patient-facing release governance permits; never activate unapproved shadow rules.
Acceptance: auditable completion report; if incomplete, explicit unfinished groups and realistic revised ETA, no fabricated 100%.

## Mandatory handoff protocol for every run
1. Fetch this checklist and the latest GitHub branch/PR head; inspect prior run's commits, tests and evidence.
2. State **previous block: PASS / PARTIAL / FAIL**, with commit hashes and missing acceptance criteria. Do not infer success from prior messages.
3. Finish any incomplete prior-block tasks first. Then execute the next block's work, commit tangible artifacts, run tests and update this file.
4. Send user a concise progress report with actual completed/total review groups and medication IDs mapped, failures, next actions.
5. If clinical guidelines conflict or independent approval is missing, mark NEEDS_REVIEW and keep patient-facing rules fail-closed.

## Immediate run verification — 2026-11-07
- User-requested automation `run_now` returned success and inline execution in this conversation; scheduled-run history had not shown an execution.
- Previous block status: **PARTIAL**. GitHub Actions passed at `672d343`, but inventory manifest and exact denominators remain unverified.
- Continue Block 1 before advancing. No medications clinically signed off by this engineering check.

## Verified inventory denominator (GitHub Actions 42332062649)
- Canonical medication IDs: **436**.
- Unique ingredient-ID sets: **233** (provisional lower bound for review groups; route/release/formulation can increase it).
- Combination medication entries: **48**.
- Inventory integrity suite: 4/4 tests passed. Duplicate IDs and missing ingredient references: none detected by passing tests.
- This is terminology coverage, NOT guideline validation or independent clinical approval.

## 2026-11-07 run: previous block PARTIAL
- Previous CI run **42341646914 FAILED** at TypeScript typecheck: inferred `reviewStatus: string` incompatible with `'NOT_STARTED'` in manifest builder. Root cause identified from job **128310416747** logs.
- Fixed status literal inference with `as const` in commit **0ed104b60a871dd6bff1caa0d0d2a0b536647ceb**; new CI result must be checked before claiming pass.
- Manifest builder and four new mapping tests committed previously; 436 canonical IDs / 233 provisional ingredient sets / 48 combination entries from earlier passing CI. Distinct formulation-group denominator remains unknown until adjudication. Clinical review 0 groups confirmed; 0 patient-facing rules activated.
- Block 2 antithrombotic reconciliation cannot be declared complete. Proceed once CI and formulation grouping are established; source-specific evidence still required.

## 2026-11-07 continuation — previous Block 1 PARTIAL
- Verified PR #37 remains open at prior head 064a05a; PR #36 was merged into main as ec1ee7e1.
- Commit 064a05a has Vercel status SUCCESS (https://vercel.com/prep-meds/prepmeds/CTBjfJXDkUfeGXj4KDwvzqLrkvbA); GitHub Actions test/typecheck result for that commit is NOT established by this status alone.
- Added research-only ASGE 2016 vs newer guideline reconciliation scaffold in docs/antithrombotic-source-reconciliation.md, commit 9a32493. This does not complete agent-level review, per-ID mapping, or clinical sign-off.
- Denominators unchanged: 436 canonical medication IDs; 233 provisional ingredient sets; 48 combination entries. Final formulation group count unknown; clinically reviewed 0 confirmed. Block 1 acceptance remains PARTIAL; no patient-facing rules activated.
- Next: inspect GitHub Actions for current head, complete formulation-level grouping, and enumerate all antithrombotic IDs for individual ASGE comparator mapping.

## 2026-11-07 continuation — CI verified; research UI wired
- Prior block status PARTIAL: formulation adjudication and per-ID clinical source mapping remain incomplete.
- GitHub Actions quality run 42345077523 completed SUCCESS at eeac28f8bf850efe770148983b280f5f5bff8a7a (https://github.com/jedmedasr/PREP-MEDS/actions/runs/42345077523). This verifies engineering checks only, not clinical accuracy.
- Added clinician-only source-specific timing comparison component (e83e3ee) and mounted it in ClinicalWorkspace (c5e1308). Shows ASGE 2016 renal-stratified apixaban high-risk interruption alongside ACG–CAG 2022 evidence limitations. No patient-facing output or automatic pathway selection.
- Latest UI commit CI/deployment remains PENDING verification; no merge.
- Inventory unchanged: 436 canonical medication IDs; 233 provisional ingredient sets; 48 combinations. Final clinically distinct groups NOT established. Clinically reviewed 0 confirmed; mapped IDs to clinically validated groups 0 confirmed.
- Next: verify latest CI; add complete source-specific timing coverage, mapping tests and formulation adjudication. Research UI must not be interpreted as clinical signoff.

## 2026-11-07 scheduled validation block — previous PARTIAL / CI failure corrected
- Inspected PR #37 head 5a4b8cb and quality run 42345991815: **FAIL**, TypeScript errors in calendar research helper (possibly undefined date components) and malformed Vitest `it.each` tuple typing. Fixed in commits f7f56ab and 523721c; new CI not yet verified.
- Added research-only calendar subtraction helper/tests in aa7ead3/a2c0007, mounted in clinician UI at 5a4b8cb. Candidate dates are NOT verified last permissible dose dates/times. No automatic patient instructions.
- Added deterministic antithrombotic canonical-ID discovery and provisional ingredient-set audit queue in 71a5fc3 with regression tests d22777e. Every discovered record has immutable ID, NOT_STARTED status, explicit ASGE 2016 source and NOT_STARTED comparison, and no clinical approval. This is an enumeration scaffold, NOT a completed per-medication comparator.
- Overall inventory: **436 canonical IDs**, **233 provisional ingredient sets**, **48 combinations** (from earlier passing CI). Final distinct ingredient/formulation group count unverified. Clinically reviewed **0 confirmed groups**; clinically validated canonical-ID mappings **0 confirmed**. Antithrombotic queue runtime counts require CI/runtime verification.
- Current block: **PARTIAL**, pending new CI and exhaustive antithrombotic class discovery/formulation review, dated primary source reconciliation, renal threshold verification, patient-safe last-dose calculation. PR #37 remains open; no merge or clinical signoff.

## 2026-11-07 06:56 ET continuation — previous block PARTIAL
- Inspected PR #37 at head 7b1b662 and previous checklist. The prior run corrected failing TypeScript/tests in f7f56ab and 523721c, but GitHub Actions fetch for 7b1b662 returned no associated PR workflow runs; a PASS cannot be asserted. Previous completed failure 42345991815 remains documented. This is an **unverified CI gate**, not evidence of a new failure.
- Finished a missing Block 1 requirement: per-canonical-ID audit metadata (status enum, last-reviewed date, review commit, source versions, test evidence, remaining issues) and deterministic canonical-to-provisional-group map in medication-validation-manifest.ts, commit 6378c1a.
- Extended antithrombotic queue with per-ID review provenance, pending issues and explicit ASGE 2016 reference, commit 117f8fa. Added cross-inventory completeness, inheritance and fail-closed comparator tests, commit adf3ee0.
- Source attachment is NOT a completed source comparison. All records remain NOT_STARTED. No group clinically signed off or patient-facing rule enabled.
- Verified prior inventory denominator: 436 canonical medication IDs, 233 provisional ingredient sets, 48 combination entries. **Mapped in manifest design:** every canonical ID is assigned a provisional ingredient-set key; new mapping tests have not yet passed CI. **Clinically validated:** 0 confirmed groups and 0 confirmed canonical-ID mappings. Final formulation-specific group count still unknown; antithrombotic queue runtime totals not yet measured.
- Block status **PARTIAL**. Latest commit CI and deployment pending; PR #37 remains open. Next: inspect CI, resolve failures, obtain actual antithrombotic queue counts, adjudicate formulations, perform agent-specific primary-source reviews and ASGE comparisons, and implement validated time calculations only in review-only mode.

## 2026-11-07 continuation — prior block PARTIAL, source comparison started
- FIRST inspected PR #37 head 17195e9, the prior checklist and antithrombotic audit queue. PR-triggered workflow lookup for 17195e9 returned **no runs**; therefore the earlier TypeScript correction and newer audit-manifest tests cannot be called PASS. CI remains unverified, not failed.
- Inspected current queue code: it creates deterministic provisional antithrombotic groups but did not emit actual runtime denominator. Added regression test that logs exact antithrombotic ID/group counts and verifies source inheritance (ab2363f); output requires next successful CI log inspection. Do not fabricate counts.
- Started substantive apixaban high-risk source comparison ledger with ASGE 2016, ACG–CAG 2022 and BSG/ESGE 2021, explicit differences and unresolved source validation/clinical dependencies (28ec5ca), plus source-separation/safety tests (63795f4). Status IN_PROGRESS, clinicalApproval=false. The source summary requires independent primary-document confirmation before clinical signoff; no CHEST/ACC/AHA/FDA reconciliation yet.
- Current verified inventory denominator remains 436 canonical medication IDs / 233 provisional ingredient sets / 48 combinations. Antithrombotic ID and provisional-group counts **not yet verified**. Completed clinically distinct review groups **0**; clinically validated ID mappings **0**. No patient-facing rule activated, no merge.
- Next: inspect CI logs and fix failures, capture exact antithrombotic counts, reconcile apixaban against original guideline tables and FDA/CHEST/ACC/AHA, then expand to dabigatran/rivaroxaban/edoxaban without borrowing apixaban renal thresholds.

## 2026-11-07 next block — prior PARTIAL, approval-gate hardening
- FIRST inspected PR #37 at d40381c, previous commits and sprint checklist. Commit-associated PR workflow lookup returned no runs for d40381c or 17195e9. Prior CI remains UNVERIFIED; do not call it PASS. PR #37 open.
- Added explicit ASGE comparator outcome union (NOT_STARTED/IN_PROGRESS/COMPARED/NOT_ADDRESSED) and fail-closed antithrombotic group approval gate, commit 5ef48fb. Requires source section, reviewer and comparison evidence or justified NOT ADDRESSED; also formulation adjudication, newer evidence, tests, distinct canonical IDs and independent approval. Existing queue remains NOT_STARTED.
- Added negative tests for incomplete comparator, missing approvals/tests, duplicate IDs, and NOT ADDRESSED rationale, plus synthetic positive controls (00aa267). No real clinical group is approved by these tests.
- Verified historical inventory denominator remains 436 canonical medication IDs / 233 provisional ingredient sets / 48 combinations. Exact antithrombotic ID/group denominator still awaiting test log or execution. Clinical reviews completed this block 0; cumulative 0; clinically validated mapped IDs 0. No patient-facing activation or merge.
- NEXT: verify latest quality workflow and capture antithrombotic counts, fix any failures, then complete original-source agent-by-agent evidence and formulation-specific mapping.

## 2026-11-07 manually triggered hourly-sprint continuation
- Scheduler accepted an immediate run of the existing hourly automation; execution took place inline in its conversation, not in an independently verified background worker.
- FIRST inspected PR #37 head b4cbdc6, prior ledger, and apixaban evidence tests. Previous block PARTIAL: clinical review still incomplete; full-head CI not verified.
- Incorporated independent SPR-001 audit finding from GitHub Actions run 42374711461: antithrombotic discovery queue 17 canonical IDs / 17 provisional ingredient groups. This is NOT proof of exhaustive coverage or clinically distinct formulation adjudication.
- Added regression assertions pinning the 17/17 denominator and zero completed ASGE comparisons/approvals (c3f3983). New commit CI still pending.
- Cumulative inventory 436 canonical IDs / 233 provisional ingredient sets / 48 combinations; 0 clinically adjudicated groups and 0 clinically approved ID mappings. No patient-facing activation, no merge.
- Next: verify full-head CI and continue primary-source medication-specific comparison; update baseline explicitly if terminology inventory is expanded.

## 2026-11-07 manual recovery execution after missing unattended report
- Scheduler accepted manual run; it executed inline, not as verified unattended background execution. Prior scheduled history still showed only 11:56Z start, so missed scheduled delivery remains unresolved.
- FIRST inspected PR #37 head 93ad4e3, prior ledger and antithrombotic tests; prior block PARTIAL because CI for latest head was not independently verified and clinical comparisons incomplete. Commit-associated PR workflow lookup for 93ad4e3 returned no runs (limited to PR-triggered first page; does not establish no CI).
- Hardened approval gate to reject whitespace-only newer-guideline and test evidence (5a3eef8) and added negative regression tests (37be7d7). Tests committed but CI not verified; no patient-facing rules activated.
- Counts unchanged: 436 canonical medication IDs mapped to 233 provisional ingredient groups (48 combination entries); antithrombotic discovery baseline 17 IDs/17 provisional groups, 0 completed ASGE comparisons, 0 clinically adjudicated/approved groups, 0 clinically validated IDs.
- Next: verify actual CI for new head, assess antithrombotic inventory completeness and primary-source comparisons. Do not claim automated unattended run success based on manual execution.

## 2026-11-07 09:26 ET scheduled continuation — previous PARTIAL
- FIRST inspected this checklist, PR #37 at head 2b645eb, the manifest builder and mapping tests. Previous Block 1 remains **PARTIAL**: clinically distinct formulation grouping is not adjudicated; no static exported inventory artifact; source-specific review incomplete.
- Current head 2b645eb had Vercel combined status **FAILURE** (deployment bU4T9B1xnMMihBTYYg8XCw8PTwNt); this does not establish the root cause. PR #37 is open and GitHub reports mergeable=false. No merge attempted.
- Added fail-closed checks for duplicate canonical IDs and empty ingredient mappings before mapping export (commit 5e079f4), plus completeness/uniqueness regression test (commit 21ef210). These are engineering safeguards, NOT clinical validation.
- New head 21ef210 had no returned combined statuses or PR workflow runs at inspection; **CI UNVERIFIED**. No tests claimed passing in this run.
- Last verified inventory denominators: **436 canonical IDs**, **233 provisional ingredient sets**, **48 combination entries**; antithrombotic discovery baseline **17 IDs / 17 provisional groups**, not proof of exhaustive class coverage. All 436 IDs have provisional mappings in manifest design, but **0/436 clinically validated mappings**. **0 clinically completed groups / final formulation-specific denominator undetermined**. ASGE comparisons completed: 0.
- Next: determine Vercel failure cause and run current-head quality checks; finish formulation adjudication and static audit export, then source-verify antithrombotic agent comparisons. No patient-facing activation or clinical signoff.

## 2026-11-07 10:26 ET scheduled continuation — previous PARTIAL, syntax blocker repaired
- FIRST inspected previous checklist, PR #37 head 1617257, manifest source/tests, and latest combined commit status. Previous Block 1 remains PARTIAL: formulation adjudication and static export unfinished; clinical reviews 0.
- Found literal `\\n` sequences embedded in TypeScript code (not string literals) in `apps/web/lib/medication-validation-manifest.ts`, introduced by earlier guard commit. These make the guard block invalid TypeScript and are a concrete build blocker. Replaced all seven literal escape sequences with real newlines, commit **90d4e6a5dac20a4209f86e2ed9f83fa753b2efb8**. No clinical rules modified.
- Prior head 1617257 had Vercel combined status FAILURE (deployment https://vercel.com/prep-meds/prepmeds/2agqTQUwbUZQwrd89BHeg9EotwkB). Failure cause is not proven by status alone; new commit CI and deployment remain UNVERIFIED.
- Last measured inventory 436 canonical IDs / 233 provisional ingredient sets / 48 combination entries; 436 provisional mappings in manifest design, **0 clinically validated ID mappings**, **0 completed clinically distinct review groups** (final denominator pending). Antithrombotic discovery baseline 17 IDs / 17 provisional groups; completed ASGE comparisons 0.
- Block 1 still PARTIAL. Next: confirm quality/build CI on 90d4e6a, finish formulation adjudication and export, then advance antithrombotic source-by-source review. No merge, clinical signoff, or patient-facing activation.

## 2026-11-07 11:27 ET continuation — prior block PARTIAL
- FIRST inspected PR #37 at ad2cdd9 and the sprint checklist; PR is open, mergeable=false. PR-triggered workflow lookup for ad2cdd9 returned zero runs; latest CI is UNVERIFIED (not PASS).
- Reviewed manifest and antithrombotic queue. The provisional ingredient-set grouping remains unadjudicated and ASGE comparators remain NOT_STARTED; no clinical signoff.
- Added fail-closed duplicate ingredient-ID and canonical group membership checks to manifest builder in a015540. These are engineering guardrails, not formulation review or clinical evidence. New commit tests/CI remain UNVERIFIED.
- Historical verified inventory: 436 canonical medication IDs, 233 provisional ingredient sets, 48 combination entries. Provisional mappings 436/436 by builder design; clinically validated mapped IDs 0/436. Final distinct formulation review-group denominator unknown; clinically completed review groups 0.
- Previous Block 1 PARTIAL; next verify CI and fix any regressions, add direct negative tests, export persistent audit manifest, adjudicate formulation splits, then proceed to antithrombotic source comparisons. No merge, patient-facing activation, or approval.

## 2026-11-07 manual continuation — previous PARTIAL; negative regressions added
- FIRST inspected prior sprint ledger, PR #37 head 044323b (open, mergeable=false), manifest and its existing positive-only test suite. Prior Block 1 remains PARTIAL; previous commits and CI cannot be marked PASS without current-head evidence.
- Enabled injection of terminology records into the manifest builder solely for deterministic negative fixtures (f951bfb); production defaults to canonical terminology dataset.
- Added negative tests for duplicate canonical IDs, empty ingredient arrays, blank ingredient IDs and duplicate ingredient IDs (cfeac66). These are unexecuted until CI/test runner verifies them; no claim of passing tests.
- No clinical review completed. Last established inventory: 436 canonical IDs provisionally mapped / 233 provisional ingredient sets / 48 combination entries. Clinically validated IDs 0/436, completed formulation-adjudicated groups 0, final formulation-specific denominator unknown. Antithrombotic baseline 17 IDs/17 provisional groups, ASGE comparisons 0.
- Blockers: PR #37 mergeability false (cause not yet established), CI for new commits not verified, formulation adjudication and static audit export outstanding, no verified source-specific antithrombotic comparisons.
- Next: verify TypeScript/tests and CI for current head, diagnose mergeability, produce version-controlled static inventory export, then adjudicate formulation distinctions and source comparisons. No merge or patient-facing activation.

## 2026-11-07 12:24 ET continuation — previous PARTIAL; inheritance regression added
- FIRST inspected previous ledger, PR #37 head 5a3494d and current combined status. GitHub combined status reports Vercel FAILURE at https://vercel.com/prep-meds/prepmeds/9sEgUBSLranaYKmtCmiicd51dqcD; PR-triggered workflow lookup returned no runs. Previous block remains PARTIAL, not PASS. PR mergeable=false; underlying reason unverified.
- Attempted Vercel build-log retrieval for deployment ID 9sEgUBSLranaYKmtCmiicd51dqcD; Vercel connector returned 404 deployment not found in available scope, so failure cause remains unknown.
- Added direct negative-inheritance regression (7f7e0e4): two canonical IDs sharing one provisional ingredient set must retain NOT_STARTED clinical status, PENDING formulation adjudication, no source versions, and no last-reviewed date. This is a committed but NOT YET EXECUTED test.
- Last established inventory: 436 provisional mapped canonical IDs / 436 total, 233 provisional ingredient sets, 48 combination entries; final formulation-specific review-group denominator undetermined; 0 clinically completed groups, 0 clinically validated mappings, 0 completed ASGE comparisons. No clinical correction or patient-facing activation.
- Blockers: failed Vercel status with inaccessible logs, no verified CI for current head, formulation adjudication/static audit export incomplete, antithrombotic source comparisons pending.
- Next: recover scoped Vercel logs or run local build/test through authorized execution environment; address failed checks before merge, then static export and formulation splits.

## 2026-11-07 13:23 ET continuation — prior PARTIAL; opt-in static export added
- FIRST inspected prior ledger, PR #37 head 618eb5d (open, mergeable=false), previous negative tests, and commit combined status: Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/Bn2acfDw56A4v2vKDC7CUNT6ySyC). No passing CI evidence for previous block. PR #36 is closed; no assumption its behavior was fully validated.
- Added opt-in deterministic snapshot export to medication manifest Vitest suite (5987e06, newline fix adc9b92). Run from apps/web with `EXPORT_MEDICATION_AUDIT=1 pnpm exec vitest run tests/medication-validation-manifest.test.ts` to generate `docs/medication-audit-manifest.json`, then inspect and commit the generated JSON. This run DID NOT execute the command, generate JSON, or verify tests; static export remains PARTIAL.
- Last established baseline: 436 canonical IDs provisionally mapped, 233 provisional ingredient groups, 48 combination entries; final formulation-specific group denominator not established; 0 clinically reviewed groups, 0 clinically validated mappings, 0 ASGE comparisons. No medication clinical correction.
- Blockers: Vercel failure cause unverified; new commits untested; PR mergeable=false; no committed generated snapshot; clinical formulation adjudication/source review pending. Next: execute export and tests in authorized runner, commit snapshot, diagnose CI, then review antithrombotic source comparisons. No merge or patient-facing activation.

## 2026-11-07 14:23 ET continuation — previous PARTIAL; approval membership safety gate
- FIRST inspected PR #37 head 786cf0d, previous sprint ledger, manifest/export test, antithrombotic queue and approval gate. Prior Block 1 remains PARTIAL: static export unexecuted, formulation-specific denominator unadjudicated, no source comparisons.
- GitHub combined status for 786cf0d: Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/67xwfzuL4a8NBxa2NYNKLokTSRrX); PR-triggered workflow lookup returned zero runs. Retrieved Vercel project/team scope; direct deployment event lookup returned 404 NOT_FOUND, so root cause and current-head test outcomes remain UNVERIFIED.
- Identified approval-gate safety gap: a complete synthetic evidence fixture could be passed with an unrelated or nonexistent canonical medication/group. Added exact group-to-canonical-ID membership verification against discovered inventory (8213bf7) and negative regression fixtures for foreign IDs, fabricated groups, partial membership and empty IDs (c4c7d88). Tests COMMITTED, NOT EXECUTED; no clinical approvals conferred.
- Last established inventory: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets, 48 combination entries; clinically completed formulation-specific groups 0 / final denominator unknown; clinically validated canonical mappings 0/436; antithrombotic discovery 17 IDs/17 provisional groups; completed ASGE 2016 comparisons 0. This run: 0 clinical reviews, 0 clinical corrections.
- Blockers: unverified CI and inaccessible Vercel deployment logs; PR #37 mergeable=false; static audit snapshot not generated/committed; formulation adjudication and ASGE source comparisons pending. Next: execute current-head tests/build and export in authorized runner, diagnose Vercel scope/status, then reconcile source evidence. No merge or patient-facing activation.

## 2026-11-07 15:26 ET continuation — previous PARTIAL; snapshot drift protection
- FIRST inspected PR #37 head 5a4b495, prior sprint ledger, audit manifest/export test, antithrombotic audit queue and tests. GitHub combined status for previous head reports Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/tD6x6Jexinziy8GN4ynWB5GSyoJF); workflow lookup returned zero runs. Previous block remains PARTIAL, not PASS.
- Fixed opt-in manifest export to compare byte-for-byte against an existing committed JSON snapshot and FAIL on drift rather than silently overwrite audit history (4c25928). When no snapshot exists, explicit opt-in still writes the initial file. Test committed, not executed; no passing CI claimed.
- Last established baseline: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets and 48 combination entries; clinically validated IDs 0/436, completed clinically distinct formulation groups 0 (final denominator unknown), antithrombotic discovery 17 IDs/17 provisional groups, ASGE comparisons 0. This run: 0 clinical reviews, 0 clinical corrections.
- Remaining: execute export and commit initial snapshot; verify current-head tests and Vercel build, diagnose PR mergeable=false, adjudicate formulation groups and reconcile original guideline evidence. No merge, signoff, or patient-facing activation.


## 2026-11-07 17:26 ET continuation — previous PARTIAL; inventory safety tests committed
- FIRST inspected previous sprint ledger, PR #45 head `e977e53` (OPEN), canonical manifest and antithrombotic audit queue. PR #37 has already merged; do not repeat its work. Previous Block 1 remains PARTIAL: no committed static snapshot, no final clinically distinct formulation denominator and no completed clinical review.
- Fixed manifest validation to reject blank canonical medication names (4b133438), preventing unreviewable inventory entries. Added negative-name and source-order-invariance regression tests (b1c1c47). Both changes are on the sprint branch; they do not change medication instructions.
- Latest commit combined GitHub status: PENDING with zero status contexts when checked. Tests/CI NOT VERIFIED; no claim of PASS. PR #45 remains separate/open and its tests must be verified before merge.
- Last established totals: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets, 48 combinations; final formulation review-group denominator UNKNOWN; 0 clinically reviewed groups, 0 clinically validated canonical mappings; 17 discovered antithrombotic IDs, 0 completed ASGE 2016 comparisons. This run: 0 clinically completed groups, 0 medication clinical corrections.
- Blockers: static manifest snapshot not generated/committed, final formulation adjudication incomplete, source-by-source ASGE comparator incomplete, CI not yet verified on this head. Next: run manifest export and tests in CI runner, commit reviewed static snapshot, adjudicate distinct formulations and begin source-specific agent comparisons. No patient-facing activation.


## 2026-11-07 18:25 ET continuation — previous PARTIAL; immutable-ID integrity fix
- FIRST inspected sprint checklist, manifest builder, existing regression suite, and PR #45 (open, mergeable=true). Prior Block 1 remains PARTIAL because static snapshot export, formulation adjudication, and current-head CI are unfinished. Prior clinical comparisons remain zero.
- Rejected leading/trailing whitespace in immutable canonical medication IDs and ingredient IDs before grouping (49936ee); added three negative regression fixtures (0fa32da). These are data-integrity safeguards, not medication-specific clinical validation. Existing group assignment and patient-facing medication guidance were not changed.
- GitHub combined commit status for 0fa32da: PENDING, zero status contexts at inspection. New tests NOT VERIFIED as passing. No deployment claimed.
- Last verified baseline: 436/436 provisional ID mappings, 233 provisional ingredient sets, 48 combination entries; final formulation-specific denominator unknown; 0 clinically completed groups and 0 clinically validated IDs. Antithrombotic discovery 17 IDs, ASGE comparisons 0. This run: 0 clinical groups completed, 0 clinical medication corrections.
- NEXT: run CI for branch head, generate and commit static manifest using explicit export, then adjudicate formulation groups and source-specific antithrombotic comparisons. PR #45 is still open; no merge or clinical signoff.


## 2026-11-07 19:24 ET continuation — previous Block 1 PARTIAL; control-character integrity gate
- FIRST inspected prior 18:25 ET handoff, current manifest/export test, and PR #45 (open at e977e53); prior Block 1 acceptance remains PARTIAL because no committed static snapshot or formulation adjudication, and no clinical comparisons are complete.
- Added control-character rejection for immutable medication IDs, ingredient IDs, and canonical labels in manifest builder (8ec764f); added three negative regression scenarios for newline, NUL, and tab corruption (77376f9). These are engineering safeguards, not medication clinical reviews. The changes have NOT been executed or confirmed by CI during this run.
- Established baseline remains 436/436 provisional canonical-ID mappings, 233 provisional ingredient sets, 48 combinations; final formulation-specific denominator unknown; 0 clinically reviewed groups, 0 clinically validated IDs, 17 discovered antithrombotic IDs, and 0 completed ASGE comparisons. This run: 0 clinical reviews and 0 clinical corrections.
- Blockers: no verified test execution on new commits; static snapshot export and formulation adjudication still pending; source-specific ASGE 2016 reconciliation not complete. PR #45 remains open; no merge or patient-facing activation.
- NEXT: run Vitest and explicit static manifest export in a runner with repository checkout, commit verified snapshot, adjudicate formulation groups, then progress antithrombotic evidence. Do not count this integrity gate as clinical signoff.


## 2026-11-07 20:26 ET continuation — previous Block 1 PARTIAL; negative-test fixture repaired
- FIRST inspected the sprint checklist, PR #45 (OPEN at e977e53), manifest builder, export test, antithrombotic queue and prior handoff. Block 1 remains PARTIAL: static snapshot export not executed/committed and final formulation denominator unknown. No clinical source comparison has been completed.
- Found a **false-positive regression risk**: the three newly added control-character tests passed literal backslash sequences (`\\n`, `\\u0000`, `\\t`) rather than actual newline/NUL/tab characters. Corrected the fixtures to actual control-character escapes in commit `6f7b5584085a3d139be36e1c9060cb6d001f93e2`. This is test correctness work, not clinical review.
- New commit test execution and CI results are NOT established; no local runner or manifest export execution occurred in this run. Do not mark the new tests as passed or the snapshot as committed.
- Baseline (last established): 436/436 provisionally mapped canonical IDs, 233 provisional ingredient sets, 48 combination entries, 17 antithrombotic IDs; final clinically distinct formulation groups UNKNOWN; clinically reviewed groups 0, clinically validated IDs 0/436, completed ASGE comparisons 0. New clinical reviews 0, clinical corrections 0.
- NEXT: execute Vitest and explicit snapshot export in a runner, verify current-head CI, commit actual generated manifest, adjudicate formulation-specific splits and perform source-linked agent comparisons. No merge or patient-facing rule activation.


## 2026-11-07 20:38 CT execution — previous Block 1 PARTIAL; deterministic manifest syntax repair
- FIRST inspected prior 20:26 ET checklist, manifest source, PR #45 (open at e977e53), and combined status for previous commit 74dca71 (Vercel SUCCESS only; application CI not verified).
- Previous continuation introduced a source syntax defect: literal `\\n` characters outside a string in `medication-validation-manifest.ts` at commit caa8f4b. Corrected to actual line breaks in commit 62cb27dd0505f9dac2188f4e50917fe4ec24589f. Earlier added permutation regression test at 74dca71 remains committed, but execution has not been verified.
- Block 1 PARTIAL: reproducible group-member sorting implemented, but static export, verified current-head CI, and formulation adjudication remain outstanding. No clinical medication recommendations changed.
- Counts from prior verified inventory: 436 canonical IDs provisionally mapped / 436 total; 233 provisional ingredient sets, 48 combinations, 17 discovered antithrombotic IDs; final formulation group denominator unknown; 0 clinically completed groups; 0 clinically approved canonical-ID mappings; 0 completed ASGE comparisons.
- NEXT: verify current-head application CI, generate and commit static manifest, adjudicate clinically distinct formulations, and begin complete ASGE agent comparisons. No clinical signoff or patient-facing activation.


## 2026-11-07 21:13 CT scheduled continuation — previous Block 1 PARTIAL; antithrombotic discovery expanded
- FIRST fetched sprint checklist, current manifest builder, PR #45 (OPEN), previous ledger and Vercel combined status for 48b894d (Vercel SUCCESS only). Static `docs/medication-audit-manifest.json` returned 404 on sprint branch: committed snapshot remains absent. No GitHub Actions test PASS established.
- Expanded research-only antithrombotic ingredient discovery to include parenteral thrombin inhibitors, less-common anticoagulants, intravenous antiplatelet agents and combination constituents (e3b7572). Added canonical-ID discovery, ASGE placeholder inheritance and fail-closed approval regression test (41c6ba8). This is discovery coverage, NOT ASGE source comparison or clinical review.
- Baseline from previously verified inventory: 436/436 provisionally mapped canonical IDs, 233 provisional ingredient sets, 48 combination entries. Expanded antithrombotic queue runtime count must be remeasured; previous 17-ID count is stale and must NOT be asserted as current. Final formulation group denominator unknown. Completed clinical review groups 0 confirmed, clinically validated ID mappings 0/436, completed ASGE comparisons 0. Clinical corrections 0.
- Block 1 remains PARTIAL: static snapshot missing, formulation adjudication unfinished, and new tests/CI unverified. No merge, clinical approval or patient-facing rule activation. NEXT: run test suite and static export in checked-out runner, commit snapshot, remeasure antithrombotic queue, then complete primary-source comparator reviews.

## 2026-11-08 continuation — previous Block 1 PARTIAL; primary-source antithrombotic evidence started
- FIRST inspected current checklist, PR #37 (MERGED), PR #45 (OPEN), manifest builder, missing static snapshot (404), existing antithrombotic discovery queue and prior CI evidence. Previous Block 1 PARTIAL: static manifest and formulation adjudication remain incomplete; prior workflow lookup for 48b894d returned no PR-triggered runs.
- Repaired literal escaped-newline syntax in antithrombotic audit queue (60f1df2). Added research-only source-linked ASGE 2016 Table 7 apixaban and Table 8 rivaroxaban renal-stratified comparisons against BSG/ESGE 2021 and ACG/CAG 2022 (2b2ac37), and source-specificity/negative-inheritance regression tests (5a43f4a). These tests have NOT been verified as passing at time of writing.
- Apixaban and rivaroxaban evidence status IN_PROGRESS only, not TESTED or CLINICALLY_REVIEWED. ASGE tables include ambiguous ranges/minimums, so no last-dose timestamp is generated. Current FDA labeling, CHEST, ACC/AHA, full formulation/indication, restart, and independent clinical review remain outstanding. No patient-facing rule activated.
- The static snapshot could not be produced reliably from connector-only source files: generating it requires executing the TypeScript terminology aggregation with repository dependencies in a checked-out runner. Local git access failed with DNS resolution error for github.com. Do not fabricate a 436-record snapshot. Export and commit in CI/checkout, then verify deterministic drift checks.
- Previously established inventory: 436 canonical IDs provisionally mapped / 436, 233 provisional ingredient sets, 48 combination entries. Final clinically distinct review-group denominator unknown. Clinically completed groups 0 confirmed; clinically validated ID mappings 0/436. Two antithrombotic ingredient comparisons IN_PROGRESS; zero completed ASGE comparisons. Expanded discovery queue runtime count not remeasured.
- Next: inspect exact-head CI, fix any errors, execute the opt-in static export and commit its generated JSON, adjudicate formulations, then extend agent-specific ASGE comparisons (dabigatran, edoxaban, warfarin, antiplatelets) and FDA/CHEST/ACC/AHA. No merge or clinical signoff.

## 2026-11-07 23:31 ET automation — previous PARTIAL, renal boundary tests added
- FIRST checked prior handoff and commit cc3ec62: Vercel combined status SUCCESS at https://vercel.com/prep-meds/prepmeds/DPQ6jZ84bZg9i8ggeMnSdLYyxRMN; GitHub PR-triggered workflow query returned ZERO runs, so no application test PASS is established. The static docs/medication-audit-manifest.json still returned 404.
- Added ASGE 2016 source-table research boundary regression tests for apixaban and rivaroxaban at CrCl 14, 15, 29, 30, 59, 60, 61, 90, 91 as applicable, plus negative cross-agent inheritance tests: d9ab158d66afae9c0255c28da3833b4f5fefa27e. Source data are research-only and NOT approved clinical logic; test execution unverified.
- Explicitly preserved apixaban CrCl 60 mL/min as UNMATCHED by literal >60 and 30–59 source strata rather than silently selecting a hold duration. This is a source-boundary data-quality issue requiring primary table adjudication, NOT a patient-facing instruction.
- Attempted repository checkout using git ls-remote; failed with DNS 'Could not resolve host: github.com'. GitHub connector writes still work, but full checked-out TypeScript execution/export unavailable here. Do not fabricate the static manifest or claim export complete.
- Cumulative last established baseline: 436/436 provisional canonical ID mappings; 233 provisional ingredient groups, 48 combinations; final clinically distinct review-group total unknown; 0 clinically completed groups, 0 clinically validated mapped IDs; 2 source comparisons IN_PROGRESS and 0 fully completed ASGE comparisons. Expanded antithrombotic queue count still unverified. Previous block PARTIAL; current block PARTIAL. Next: verify CI, run checked-out manifest export, resolve renal table boundary and complete FDA/CHEST/ACC-AHA comparisons before clinical review. No merge or patient-facing activation.

## 2026-11-08 scheduled continuation — previous PARTIAL; research-only renal lookup guarded
- FIRST inspected prior 23:31 ET handoff, PR #45 (OPEN), PR #36 (MERGED), existing antithrombotic comparison/test source, missing docs/medication-audit-manifest.json (404), and prior eaed8c6 combined status (Vercel SUCCESS only; not application CI PASS). Previous block PARTIAL.
- Added fail-closed, research-only ASGE 2016 renal-stratum lookup (61e2631), returning null on ambiguous/uncovered thresholds, missing/nonfinite CrCl, or unsupported agents. Added explicit apixaban CrCl 60 unresolved boundary, rivaroxaban 60/90/91, and negative inheritance tests (52db369). Not connected to patient instructions or approved clinical rules. Tests committed but NOT executed or verified passing.
- Static manifest snapshot still ABSENT. Do not fabricate the full canonical dataset; requires checked-out TypeScript exporter and committed generated JSON. No clinical comparisons completed; apixaban and rivaroxaban remain IN_PROGRESS and source discrepancies require independent primary-document adjudication.
- Previously established inventory: 436/436 provisionally mapped canonical IDs, 233 provisional ingredient groups, 48 combination entries; clinically distinct formulation-group denominator unknown; 0 clinically completed groups and 0 clinically validated canonical mappings. Expanded antithrombotic queue size unverified. ASGE fully completed comparisons 0. This block: 0 completed clinical groups, 0 clinical medication corrections.
- Next: run exact-head TypeScript/Vitest, fix failures, execute/commit static export, adjudicate primary ASGE boundary against original PDF, then extend FDA/CHEST/ACC-AHA source comparisons. No merge or clinical activation.

## 2026-11-08 execution — previous PARTIAL; per-ID ASGE research inheritance gate
- FIRST inspected previous block, prior 0fa64ea commit Vercel SUCCESS only, PR #45 OPEN, PR #36 MERGED, antithrombotic research source and tests, and missing static manifest (404). Previous block PARTIAL. No evidence of application CI pass for preceding head.
- Added canonical antithrombotic ID-to-constituent research comparator coverage (18d0d19) and completeness/combination negative-inheritance tests (822afa9). Source comparisons for apixaban and rivaroxaban remain IN_PROGRESS, all other constituents NOT_STARTED; no group or canonical ID is marked ASGE-complete or clinically approved. This prevents confusing a source-linked comparator with complete clinical signoff. No clinical rule changes.
- Static docs/medication-audit-manifest.json remains absent. Do not fabricate data from the previously counted inventory; checkout/TypeScript export is still required. Previously established 436/436 provisional canonical mappings, 233 provisional ingredient sets, 48 combinations; clinically distinct formulation denominator UNKNOWN; 0 clinically completed groups, 0 clinically validated mapped IDs. Expanded antithrombotic discovery count must be measured by execution; do not repeat stale 17-ID count as current. This execution: 0 completed clinical groups, 0 medication clinical corrections, 2 research-only comparison groups still in progress, 0 completed ASGE comparisons.
- NEXT: run checked-out manifest exporter and full CI; commit verified snapshot, adjudicate formulation-specific groups and ASGE source boundary, expand source-by-source comparisons. No merge, patient-facing activation, or clinical signoff.

## 2026-11-08 follow-up — previous PARTIAL; failed Vercel status discovered
- FIRST inspected prior ledger and latest source, absent static manifest (404), PR #45 OPEN, and preceding c3ef620 combined status. Contrary to prior unverified deployment wording, c3ef620 currently reports **Vercel FAILURE** at https://vercel.com/prep-meds/prepmeds/9BPwVhfmF4sYnxs9D1jqT3XXL35V ; PR-triggered GitHub workflow lookup returns zero runs. Previous block PARTIAL; CI/deployment gate FAIL until diagnosed.
- Added research-only comparator completeness regression cases (80c331b) asserting apixaban/rivaroxaban remain IN_PROGRESS/unapproved with missing FDA/CHEST/ACC comparison and null precise ACG-CAG interruption timing; negative cases cover ASGE apixaban CrCl=60, warfarin noninheritance and invalid CrCl. Tests committed, execution NOT verified.
- Static manifest remains ABSENT; no verified runner/export. Previously established provisional inventory 436/436 IDs, 233 ingredient sets, 48 combinations. Final clinically distinct group count unknown; completed clinical groups 0, clinically validated IDs 0/436, completed ASGE comparisons 0, two IN_PROGRESS. No clinical corrections or patient-facing changes.
- Next: diagnose failed Vercel deployment using build logs, verify current-head TypeScript/Vitest, run and commit canonical static export, then resume source adjudication. Do not merge or activate clinical rules.

## 2026-11-08 continuation — previous PARTIAL; snapshot generation gate and workflow committed
- FIRST inspected previous ledger, prior d572f72 commit status (Vercel FAILURE), PR #45 OPEN, manifest builder, research comparisons and missing static JSON (404). Prior block PARTIAL and deployment gate FAIL. Do not equate Vercel checks with full application CI.
- Added deterministic snapshot completeness/drift test (a33038f) that fails when the static manifest is absent, validates every canonical ID against generated groups, and permits first write only with EXPORT_MEDICATION_AUDIT=1. Added checkout-based export/commit workflow (0f72459) and push trigger (3cf0711) to produce real data instead of a fabricated snapshot. Workflow execution and output commit NOT YET VERIFIED; static manifest still absent at inspection.
- New code changes are engineering only; no clinical guidance changed. No new completed reviews, no new medication-specific clinical corrections. Previously verified provisional totals 436/436 IDs, 233 ingredient sets, 48 combinations; final distinct formulation-group denominator UNKNOWN. Clinically completed groups 0; clinically validated mappings 0/436; apixaban/rivaroxaban IN_PROGRESS; completed ASGE comparisons 0.
- Current-head combined status returned zero contexts; PR-triggered workflow lookup zero runs. Verify branch push workflow in Actions, investigate failure if present, verify generated JSON, and run quality/build. If GitHub Actions cannot push, record exact error and use available GitHub write path with actual generated data. No merge or clinical signoff.

## 2026-11-08 03:00 CT continuation — previous PARTIAL; manifest workflow push race diagnosed
- FIRST inspected previous sprint ledger, PR #45 (OPEN), missing static manifest (404), current manifest builder, failed export run 42462702998 and exact logs. Previous block PARTIAL; manifest not committed.
- Run https://github.com/jedmedasr/PREP-MEDS/actions/runs/42462702998 passed dependency installation and the 1-test Vitest manifest generation step, generated a 10,283-line JSON snapshot, and committed it locally as 7048dbe. The subsequent push failed with non-fast-forward rejection because other sprint commits advanced the branch. This is NOT an authorization failure or failed manifest-generation test.
- Updated export workflow to fetch/rebase onto latest branch before non-force push (38fe1b2), repaired accidental escaped newline formatting in YAML (3f44a7c). A workflow run for 38fe1b2 was observed IN_PROGRESS (42465365011); no successful remote snapshot or final CI claimed yet.
- Last established inventory: 436/436 provisionally mapped canonical IDs; 233 provisional ingredient sets; 48 combination entries; final clinically distinct formulation-group denominator UNKNOWN. Clinically reviewed groups 0 confirmed; clinically validated IDs 0/436; ASGE fully completed comparisons 0. This run: 0 completed clinical groups, 0 medication clinical corrections.
- Next: inspect 42465365011 logs and latest branch for docs/medication-audit-manifest.json; rerun on repaired workflow head if needed, verify full quality/build and Vercel, then resume agent-level guideline comparisons. No merge, patient-facing activation or clinical signoff.

## 2026-11-08 continuation — static manifest published, export race repaired
- FIRST verified previous export runs and fetched committed `docs/medication-audit-manifest.json` from sprint branch. Run 42466578047 SUCCESS and remote manifest now exists: 436 canonical medication IDs, 233 provisional ingredient sets, 48 combinations. This is inventory mapping only, NOT clinical review.
- Run 42466582944 failed only when a concurrent export pushed first: remote ref advanced from 0d9eb23 to 245673f; no evidence of clinical or manifest test failure. Added byte-for-byte remote snapshot verification on rejected push (1e3d369) to avoid false failures for identical concurrent exports.
- Existing quality workflow triggers only main/pull_request, so no full branch quality evidence. Vercel status for snapshot head 245673f is FAILURE, reason not yet verified. PR #45 remains OPEN. Clinically completed review groups 0/unknown final formulation groups; validated canonical IDs 0/436; completed ASGE comparisons 0. This execution 0 new clinical reviews and 0 clinical corrections.
- NEXT: run full quality/typecheck/Vitest/build against exact head, inspect Vercel logs, reconcile final formulation groups, and continue antithrombotic source-by-source review. No merge or clinical signoff.

## 2026-11-08 04:26 ET — audit manifest regression gate (PARTIAL)
- FIRST inspected prior block, static manifest, latest export CI and PRs #37/#46. Previous block PARTIAL. Export run 42466778643 now SUCCESS; manifest is committed and parseable. PR #37 MERGED; PR #46 OPEN at 3cb64eb (separate integration candidate).
- Manifest confirms 436 canonical IDs mapped to 233 provisional ingredient groups, 48 combination entries. All 233 group formulation adjudications remain pending; 436 per-ID clinical statuses NOT_STARTED. Final clinically distinct formulation denominator still unknown; 0 completed clinical groups, 0 clinically validated IDs, 0 ASGE 2016 comparisons completed.
- Added a real Vitest regression gate at apps/web/lib/__tests__/medication-audit-manifest-integrity.test.ts (a1c20e6): exact canonical ID equality/uniqueness, one-to-one provisional group inheritance and no premature clinical signoff. Test execution/CI on this exact commit NOT VERIFIED; do not claim PASS.
- Previous Vercel status was FAILURE on 245673f; current production commit/functionality not verified. PR #45 head differs from sprint branch, so this new test has not automatically entered PR CI. No clinical corrections or activation.
- NEXT: execute this test and full quality on exact branch head, resolve failures, inspect Vercel logs, then prioritize antithrombotic ASGE 2016 individual comparisons with explicit source-version records. Preserve PR #46 integration work without merging unverified clinical rules.

## 2026-11-08 05:26 ET — combination inheritance regression (PARTIAL)
- FIRST inspected prior checklist and clinical ledger, PR #46 and latest branch workflow history. Previous block **PARTIAL**: static audit manifest and its mapping tests exist, but final formulation adjudication, source-complete reviews, current-head CI and production verification are unfinished.
- Latest directly observed export workflow run **42466778643 SUCCESS**, but it applies to earlier commit 1e3d369, not this run's head. PR #46 remains open and mergeable with independent engineering review missing; do not conflate eight PR checks with sprint-branch test verification.
- Added substantive Vitest assertions for **all canonical combination ingredient memberships** and **negative cross-group inheritance** in commit **0999256a437dcefc489d00f1f38827f2dc8d0cd8**. These guard against silently treating a combination medication as a single-ingredient product or inheriting evidence from another ingredient group.
- Test execution and CI on commit 0999256: **NOT VERIFIED**; no claims of passing tests. No patient-facing rules changed.
- Confirmed inventory: **436/436 canonical IDs provisionally mapped**, **233 provisional ingredient-set groups**, **48 combination entries**. Final clinically distinct formulation group denominator **NOT ESTABLISHED**. Clinical reviews fully completed this run **0**; cumulative clinically reviewed **0**; clinically validated canonical IDs **0/436**. The separate apixaban source-comparison document has progressed but remains IN_PROGRESS, not clinically reviewed.
- Next: run full Vitest/typecheck/build on exact head, adjudicate formulation splits and reconcile antithrombotic ASGE source comparisons and clinical tests. Investigate Vercel failure before production claims; do not merge PR #46 until independent engineering review is satisfied.

## 2026-11-08 06:26 ET — clinician review evidence-revision gate (PARTIAL)
- Previous block **PARTIAL**: 436 canonical IDs provisionally mapped into 233 ingredient sets; 48 combination entries; final formulation denominator, clinical source completeness and exact-head CI remain outstanding. Previous commits 0999256 and c705077 documented; no prior run's new tests independently verified.
- Implemented isolated, research-only pure-function gate in `apps/web/lib/clinical-evidence-review-gate.ts` at **ffd00cf**. Requires affirmative clinician decision, reviewer identity/time, exact evidence hash/group, HTTPS source links, adjudicated formulation, completed evidence tests, no blocking issues, and exact canonical-ID/source-link mapping. Rejects stale approvals after source/mapping/evidence changes.
- Added 3 Vitest scenarios with negative checks in **3d20a6e**. These tests are **COMMITTED, NOT EXECUTED/CI-VERIFIED**. This is not a connected UI/authentication/persistent audit endpoint; it does not activate patient instructions or claim clinical approval.
- Totals: 436/436 canonical IDs provisionally mapped, 233 provisional ingredient groups, 48 combinations; final clinical formulation-group denominator unknown; clinical groups fully reviewed 0 confirmed; clinically validated IDs 0/436; this run 0 completed medication reviews and 0 medication corrections.
- NEXT: execute tests/typecheck on exact branch head, wire the review gate to authenticated clinician-only UI and durable immutable audit, add evidence-version hash generation, then verify source-linked antithrombotic mappings. No merge or production validation claimed.


### 2026-11-08 09:26 ET — review gate hardening checkpoint (PARTIAL)
- Previous block PARTIAL: clinical groups approved 0 confirmed, final formulation-group denominator not adjudicated, exact-head CI unverified. Existing manifest records 436 canonical IDs, 233 provisional ingredient sets, 48 combination entries; all 436 have provisional ingredient-set mappings, **not validated formulation mappings**.
- Inspected prior sprint checklist, audit manifest, antithrombotic ledger and review-gate code. Repaired timezone-less clinician review acceptance and fail-open duplicate source links / malformed canonical mapping IDs in `apps/web/lib/clinical-evidence-review-gate.ts` commit `12eda9e7d3ecf55648677681a69c03c7da3421d5`.
- Added focused Vitest regression cases for timezone offsets, timezone-less dates, duplicate links, blank and noncanonical IDs commit `e4e91842db4370b40dbc11b17e23393ff28422ff`.
- GitHub PR-triggered workflow lookup for exact test commit returned 0 runs (not proof that no push workflow exists); test execution remains **UNVERIFIED**. Vercel `list_deployments(app=prep-meds)` returned zero matching deployments; production commit and behavior **UNVERIFIED**. No PR merged and no patient rules activated.
- New clinical review groups completed: **0**; cumulative clinician-reviewed groups **0 confirmed**; mapped canonical IDs **436/436 provisional ingredient sets**, **0/436 confirmed complete clinical evidence**; final clinically distinct review-group denominator unknown (233 provisional sets is not final). Blocker: authenticated review UI and immutable audit persistence absent, exact-head CI unavailable, medication-specific source/mapping completeness outstanding.
- NEXT: execute exact-head Vitest/typecheck, connect authenticated clinician review and evidence revision persistence; clinical agent continues apixaban source verification and canonical formulation mapping independently. Do not mark any medication approved on gate tests alone.

### 2026-11-08 10:29 ET — antithrombotic scenario boundary checkpoint (PARTIAL)
- Prior Block 1 PARTIAL: 436 canonical IDs / 233 provisional ingredient sets / 48 combinations; formulation adjudication unfinished. Prior Block 2 PARTIAL: antithrombotic evidence incomplete and not clinically approved. Read sprint checklist, source reconciliation, manifest builder, research lookup/tests; inspected PR #36/#37/#46 (all merged).
- This run: research-only adult oral apixaban/rivaroxaban high-risk EGD/colonoscopy/combined scenario gate committed `6e91f16ecdd6bbcf745b5a014a0bfb966bead904`; regression cases for CrCl 60/59.5/29.5, 30/29, low/unknown procedure risk, pediatric/unknown formulation and cross-agent inheritance committed `4c30a235373d6865e138a44baef58b61d061ab00`. Existing historical ASGE Table 7/8 comparisons preserved; source reconciliation in `docs/antithrombotic-source-reconciliation.md` remains the clinical reference. Research lookup intentionally cannot generate a hold instruction.
- Tests added but **NOT EXECUTED**; GitHub combined-status endpoint returned empty statuses for exact commit `4c30a235`, not a CI pass. Vercel `list_deployments(app=prep-meds)` returned 0 records; production unverified. No PR or merge created.
- Exact clinical completion this run: **0** groups; cumulative **0 confirmed** fully clinically reviewed; final distinct formulation-group denominator **unknown** (233 provisional ingredient sets only); 436/436 canonical IDs provisionally mapped, **0/436** with complete tested clinical evidence confirmed; 0 clinical approvals, 0 patient rule activations.
- NEXT: run exact-head Vitest/typecheck and resolve any failures; adjudicate apixaban formulation and FDA label currentness, then source-complete all antithrombotics and map ASGE comparisons to canonical IDs; build authenticated clinician Mark Reviewed with durable revision audit separately. Do not claim clinical review from passing tests.

### 2026-11-08 11:23 ET — evidence approval timestamp regression checkpoint (PARTIAL)
- Previous block: **PARTIAL**. Inspected sprint checkpoint and source reconciliation: 436 canonical IDs provisionally mapped to 233 ingredient sets; 48 combination entries; final clinically distinct formulation-group denominator unknown; zero complete clinical evidence IDs confirmed; apixaban evidence remains IN_PROGRESS. Earlier exact-head CI/deployment results unverified.
- This execution: reject future-dated clinical review timestamps beyond 5-minute clock skew in `apps/web/lib/clinical-evidence-review-gate.ts`, commit `186eb5f7d8161aaa0e817dad0ce15de75b9fe3bc`; add Vitest regression for future timestamp, exact five-minute boundary, stale evidence hash, incorrect mapped medication and untested/unresolved evidence, commit `8f8c0927d81f922bf669f2c8830727029566900c`.
- Test cases **committed but not executed**; no CI PASS claimed. No authenticated review UI, database persistence, production verification, clinical signoff or patient-facing activation claimed.
- Review groups completed this run **0**, cumulative fully validated **0 confirmed**; canonical IDs provisionally mapped **436/436**, IDs with complete tested clinical evidence **0/436 confirmed**. Next: execute Vitest/typecheck on exact branch head, finish authenticated review audit, and resolve apixaban formulation/renal evidence with clinical agent. Do not promote clinical status from regression test additions.

### 2026-11-08 12:22 ET — clinician evidence-gate regression checkpoint (PARTIAL)
- Previous block **PARTIAL**: 436/436 canonical IDs provisionally ingredient-mapped, 233 provisional ingredient sets, 48 combination entries; final formulation review-group denominator unadjudicated; 0/436 complete tested clinical evidence confirmed. Prior clinical evidence addendum records apixaban ASGE Table 7 CrCl=60 gap; no clinician signoff.
- Added `apps/web/tests/clinical-review-boundary-regression.test.ts` in commit `a93ab7c0b17fcdb1c5249887cc4c4a986c3b9a88`: six focused Vitest scenarios verifying exact evidence hash, preservation of ASGE/source links, no cross-drug canonical mapping, unresolved CrCl boundary blocking, formulation and test prerequisites, and explicit reviewer decision. **Committed, not executed.** A passing pure predicate would not establish authenticated reviewer identity or durable audit persistence.
- PR-triggered GitHub workflow lookup on exact commit returned zero runs; **no CI pass** can be claimed. No Vercel production verification, merge, or patient-facing activation this block.
- Clinical groups completed this run **0**, cumulative fully validated **0 confirmed**; mapped canonical IDs **436/436 provisional**, complete tested clinical evidence **0/436 confirmed**. Next engineering action: execute exact-head tests and typecheck, connect authenticated Mark Reviewed UI and immutable evidence audit; clinical evidence agent separately finishes apixaban and proceeds to rivaroxaban.
